Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

NCT ID: NCT06627517

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-22
• Study Completion Date: 2025-12-31

Brief Summary

The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. The study device does not replace long-acting, correction, or mealtime insulin. The study will involve applying the study device before bed for a period of 13 weeks. The overall study length is approximately 17 weeks.

The study aims to evaluate whether the study device is safe and if it lowers blood sugar levels in people who have consistently high blood sugar during sleep and at wake.

Conditions

Type 1 Diabetes Mellitus; Sleep Quality

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Overnight wear of study device

Subjects will wear the study device during sleep in addition to their usual basal/bolus therapy.

Group Type: EXPERIMENTAL

Episodic overnight patch pump

Intervention Type: DEVICE

Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.

Interventions

Episodic overnight patch pump

Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. ≥18 years of age at time of consent

2. Clinical diagnosis of T1D for ≥ 6 months with a stable insulin regimen for ≥ 30 days.

3. Using a basal-bolus regimen with multiple daily injections of insulin or doses of inhaled insulin for ≥ 3 months with a stable basal dosing regimen over the previous 30 days

4. If using a non-insulin glucose-lowering drug, (e.g. GLP-1 agonists, SGLT2 inhibitors), must have a stable dose for ≥ 30 days

5. If using a weight loss medication, must be on a stable dose for ≥ 30 days

6. Using insulin lispro or insulin aspart as bolus insulin or able to obtain for the duration of the study

5. If using a weight loss medication, must be on a stable dose for ≥ 30 days 6. Using insulin lispro or insulin aspart as bolus insulin or able to obtain for the duration of the study 7. Using CGM (real-time or intermittent scanning) for ≥ 3 months (with at least 50% use), and at least 85% use in the prior 14 days 8. Using Dexcom G6 or able to obtain for the duration of the study 9. Using an iPhone as part of daily life or able to obtain for the duration of the study 10. Recurrent nocturnal hyperglycemia, defined as ≥ 7 of the previous 14 days with a nighttime glucose value > 180 mg/dL.

• Nighttime is defined at the discretion of the investigator and is intended to be the time period from when the subject goes to bed to when they get up in the morning 11. Negative baseline pregnancy test. Females of childbearing potential, willing to use an adequate method of birth control for the duration of the study.
• Adequate methods of birth control include hormonal contraceptives, intrauterine devices, or double barrier contraception, e.g., condom + diaphragm, condom or diaphragm + spermicidal gel, or foam.
• Menopause is defined as one year without menses; if in question, a follicle stimulating hormone of >40 U/ml must be documented.
• Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented as applicable.

12. Availability of a relative or acquaintance residing within 15 minutes of the subject and willing to be the subject's care partner throughout the study.

• The care partner must be willing to be trained on how to use the Dexcom Follow app and administer glucagon.
• The care partner must be willing to contact the subject upon a low or high alarm, provide aid to the subject, including glucagon administration, and/or contact emergency services.

13. Willing to share access to CGM data with the Sponsor through the Dexcom Clarity app 14. No medical, psychiatric, or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study. This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, and other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse.

Exclusion Criteria

1. Use of or plan to use insulin pump therapy during the study period.

2. Use of basal insulin for ≥ 60% of the total daily insulin dose on average over the last week per subject report.

3. Pregnant, lactating, or plans to become pregnant in the next 17 weeks. A negative serum or urine pregnancy test is required for all females of child-bearing potential.

4. Known stage 4/5 renal failure or on dialysis

5. Using Hydroxyurea medication

6. Current or anticipated acute use of corticosteroids (other than topical or inhaled) or other medications that have a known effect on glycemic variability during the time period of the study

7. Anticipated initiation of a weight loss medication and/or titration during the study period

8. Alcohol or drug use that would reduce sensitivity to symptoms of hypoglycemia or hinder appropriate decision-making in the judgment of the investigator.

9. Use of electrically powered implant(s) that may be susceptible to RF interference, such as cardiac pacemakers, spinal cord stimulators, or implantable cardioverter-defibrillators.

10. Severe hypoglycemia (defined as requiring 3rd party assistance and/or loss of consciousness or seizure) within 90 days prior to screening.

11. Diabetic ketoacidosis (DKA) diagnosed at a health care facility within 90 days prior to screening

12. Use of an investigational drug in the 30 days prior to screening.

13. Employed by or has immediate family members employed by Luna Health; is directly involved in conducting the clinical study; has a direct supervisor at the place of employment who is also directly involved in conducting the clinical study (as a study investigator, coordinator, etc.); or has a first-degree relative who is directly involved in conducting the clinical study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Luna Diabetes

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeremy H Pettus, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

Diablo Clinical Research

Walnut Creek, California, United States

Barbara Davis Center for Diabetes

Aurora, Colorado, United States

International Diabetes Center

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

LH2024-01

Identifier Type: -

Identifier Source: org_study_id